Spl-figure-01 (Spl Figure 01)
Metoprolol Succinate Tablet, Extended Release
Product Images NDC 72516-033
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 72516-033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Oryza Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Spl-figure-02 (Spl Figure 02)
This is a medical document presenting the results of a study on the use of Wetoprolol Succinate in patients with heart failure. The results indicate that Wetoprolol Succinate helps to reduce total mortality and hospitalization due to heart failure. The document also presents the results for subgroups of patients based on various factors such as race, gender, and medical history. The study also shows the relative risk and confidence interval for myocardial infarction.*
Spl-figure-04 (Spl Figure 04)
Each tablet contains Metoprolol Succinate and Metoprolol Tarat in different amounts. The tablets are for oral use and come in extended-release form. The medication should be stored at a controlled room temperature and protected from moisture. It is important to keep the tablets out of reach of children. The pharmaceutical company, Oryza Pharmaceuticals, Inc. manufactured the tablets for RxOnly use. The description is not available for the illegible text.*
Spl-figure-05 (Spl Figure 05)
Spl-figure-06 (Spl Figure 06)
This is a description of medications containing Metoprolol Succinate and Metoprolol Tartrate. The dosage and usage details for Metoprolol Succinate are provided in the package insert, and the tablets should be stored at a controlled room temperature. The medication is manufactured by Oyia Pharmaceuticals in Coral Springs, FL and by Visum Pharmaceutical Co. in Halou, China. The text also contains a warning to keep all medications out of the reach of children.*
Spl-figure-07 (Spl Figure 07)
This is a medication description for Metoprolol Succinate Extended-Release Tablets manufactured by Oryza Pharmaceuticals. Each tablet contains 180 mg of metoprolol succinate equivalent to 200 mg of metoprolol artate. The dosage and usage instructions are provided in the package insert. It should be stored at a controlled room temperature of 25°C (77°F), between 15°C to 30°C (59°F-86°F), and protected from moisture. The warning advises against keeping the medication accessible to children. The NDC code is 72516-033-01.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
